Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Acute Kidney Injury D058186 34 associated lipids
Airway Remodeling D056151 3 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Hypoalphalipoproteinemias D052456 5 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Cholecystitis, Acute D041881 1 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Stenosis D023921 6 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Stroke D020521 32 associated lipids
Latex Hypersensitivity D020315 1 associated lipids
Intracranial Hemorrhage, Hypertensive D020299 1 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Venous Thrombosis D020246 11 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Carotid Artery Injuries D020212 8 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Basal Ganglia Hemorrhage D020145 1 associated lipids
Thrombophilia D019851 6 associated lipids
Endotoxemia D019446 27 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Atrial Premature Complexes D018880 1 associated lipids
Sepsis D018805 11 associated lipids
Systemic Inflammatory Response Syndrome D018746 4 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Osteoblastoma D018215 1 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
beta-Thalassemia D017086 5 associated lipids
Carotid Stenosis D016893 15 associated lipids
Death, Sudden, Cardiac D016757 12 associated lipids
Yang Deficiency D016711 3 associated lipids
Diabetes, Gestational D016640 8 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Peripheral Vascular Diseases D016491 8 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bacteremia D016470 9 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Myocardial Reperfusion Injury D015428 20 associated lipids
Reperfusion Injury D015427 65 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Wounds and Injuries D014947 20 associated lipids
Weil Disease D014895 2 associated lipids
Granulomatosis with Polyangiitis D014890 5 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Vascular Diseases D014652 16 associated lipids
Varicose Veins D014648 7 associated lipids
Uveitis D014605 14 associated lipids
Uterine Neoplasms D014594 18 associated lipids
Uremia D014511 33 associated lipids
Ulcer D014456 16 associated lipids
Tooth, Impacted D014095 9 associated lipids
Thrombosis D013927 49 associated lipids
Thromboembolism D013923 6 associated lipids
Thrombocytopenia D013921 15 associated lipids
Thrombocythemia, Essential D013920 9 associated lipids
Thromboangiitis Obliterans D013919 4 associated lipids
Thrombasthenia D013915 4 associated lipids
Takayasu Arteritis D013625 3 associated lipids
Tachycardia, Supraventricular D013617 3 associated lipids
Tachycardia, Paroxysmal D013614 2 associated lipids
Tachycardia D013610 7 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Strongyle Infections, Equine D013319 1 associated lipids
Streptococcal Infections D013290 4 associated lipids
Stomach Volvulus D013277 1 associated lipids
Stomach Ulcer D013276 75 associated lipids
Gastric Dilatation D013271 1 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Sneezing D012912 6 associated lipids
Shock, Septic D012772 11 associated lipids
Shock D012769 11 associated lipids
Seizures D012640 87 associated lipids
Sclerosis D012598 5 associated lipids
Scleroderma, Systemic D012595 16 associated lipids
Salmonella Infections, Animal D012481 9 associated lipids
Rhinitis D012220 10 associated lipids
Retinal Vein Occlusion D012170 2 associated lipids
Retinal Diseases D012164 4 associated lipids
Retinal Detachment D012163 10 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Respiratory Hypersensitivity D012130 18 associated lipids
Respiratory Distress Syndrome, Adult D012128 15 associated lipids
Respiration Disorders D012120 5 associated lipids
Renal Artery Obstruction D012078 8 associated lipids
Raynaud Disease D011928 7 associated lipids
Radiculopathy D011843 1 associated lipids
Radiation Injuries, Experimental D011833 11 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Purpura, Schoenlein-Henoch D011695 5 associated lipids
Pulmonary Heart Disease D011660 2 associated lipids
Pulmonary Embolism D011655 5 associated lipids
Pulmonary Edema D011654 23 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Ersöz G et al. Effect of submaximal and incremental upper extremity exercise on platelet function and the role of blood shear stress. 2002 Thromb. Res. pmid:12676189
Buchanan MR et al. Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase. 1982 Thromb. Res. pmid:7071811
Umemura K et al. Effect of dietary docosahexaenoic acid in the rat middle cerebral artery thrombosis model. 1995 Thromb. Res. pmid:7660354
Küster LJ et al. Mechanism of PAF-induced platelet aggregation in man. 1986 Thromb. Res. pmid:3764802
Ali M et al. Synthesis of prostaglandin D2 and thromboxane B2 by human platelets. 1977 Thromb. Res. pmid:918907
Marasini B et al. Cigarette smoking and platelet function. 1986 Thromb. Res. pmid:3787563
Matsuo T et al. A new thrombin inhibitor MD805 and thrombocytopenia encountered with heparin hemodialysis. 1986 Thromb. Res. pmid:3787568
Neiman J et al. Composition of platelet phosphatidylinositol and phosphatidylcholine after ethanol withdrawal. 1987 Thromb. Res. pmid:3603426
Jørgensen KA et al. The survival of pig to rabbit renal xenografts during inhibition of thromboxane synthesis. 1983 Thromb. Res. pmid:6364449
Naran NH and Chetty N The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects. 1997 Thromb. Res. pmid:9556227
Todd MH et al. The involvement of prostaglandins and thromboxanes in the response to pulmonary embolism in anaesthetized rabbits and isolated perfused lungs. 1983 Thromb. Res. pmid:6687961
Togna GI et al. Cisplatin triggers platelet activation. 2000 Thromb. Res. pmid:10973681
Vesterqvist O et al. In vivo production of thromboxane in acute human myocardial infarction: a preliminary study. 1985 Thromb. Res. pmid:3992528
Küster LJ and Frölich JC PAF-induced platelet aggregation and TXB2 formation. 1989 Thromb. Res. pmid:2922704
Han P et al. Inhibition of platelet function of antiarrhythmic drugs, verapamil and disopyramide. 1982 Thromb. Haemost. pmid:7101234
Miller KW and Keith JC Effect of thromboxane synthetase inhibition on platelet function and morphology during ovine pregnancy-induced hypertension. 1988 Thromb. Haemost. pmid:3238644
Teng CM et al. ADP-mimicking platelet aggregation caused by rugosin E, an ellagitannin isolated from Rosa rugosa Thunb. 1997 Thromb. Haemost. pmid:9066010
Santilli F et al. Effects of high-amount-high-intensity exercise on in vivo platelet activation: modulation by lipid peroxidation and AGE/RAGE axis. 2013 Thromb. Haemost. pmid:24030807
Joseph S et al. Effect of the polyamine-spermine on agonist-induced human platelet activation--specific inhibition of "aggregation-independent" events induced by thrombin, but not by collagen, thromboxane mimetic, phorbol ester or calcium ionophore. 1987 Thromb. Haemost. pmid:3110996
di Minno G et al. Effects of any epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets. 1981 Thromb. Haemost. pmid:6266066
Pampolina C and McNicol A Streptococcus sanguis-induced platelet activation involves two waves of tyrosine phosphorylation mediated by FcgammaRIIA and alphaIIbbeta3. 2005 Thromb. Haemost. pmid:15886812
Jilma-Stohlawetz P et al. Impaired platelet function among platelet donors. 2001 Thromb. Haemost. pmid:11583322
Dejana E et al. Bleeding time in rats: a comparison of different experimental conditions. 1982 Thromb. Haemost. pmid:6753230
Strano A et al. Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients. 1982 Thromb. Haemost. pmid:6753232
Hansen JB et al. The effect of lipopolysaccharides (LPS) on generation of thromboxane A2 and thromboplastin activity in whole blood of males, females and females on oral contraceptives. 1989 Thromb. Haemost. pmid:2799762
Lepäntalo A et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. 2006 Thromb. Haemost. pmid:16493486
Matsumoto M et al. Thromboxane generation in patients with essential hypertension or cerebrovascular disease and effect of oral aspirin. 1980 Thromb. Haemost. pmid:7423441
Carter AJ et al. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis--effect of a thromboxane synthase inhibitor. 1984 Thromb. Haemost. pmid:6377567
Spectre G et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. 2011 Thromb. Haemost. pmid:21800009
Honey AC et al. Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit. 1986 Thromb. Haemost. pmid:3775692
Gresele P et al. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. 1990 Thromb. Haemost. pmid:2274931
Krishnamurthi S et al. Effect of pyridoxal 5'-phosphate (PALP) on human platelet aggregation, dense granule release and thromboxane B2 generation--role of Schiff base formation. 1982 Thromb. Haemost. pmid:6891107
Chen SL et al. Chlorobutanol, a preservative of desmopressin, inhibits human platelet aggregation and release in vitro. 1990 Thromb. Haemost. pmid:2096493
Martinuzzo ME et al. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. 1993 Thromb. Haemost. pmid:8115993
Kyrle PA et al. Thromboxane A2 and prostacyclin generation in the microvasculature of patients with atherosclerosis--effect of low-dose aspirin. 1989 Thromb. Haemost. pmid:2508252
Stratta P et al. Warning: platelet factor 4, beta-thromboglobulin and thromboxane in donor's plasma units. 1983 Thromb. Haemost. pmid:6189235
Scharf RE In vitro thromboxane synthesis of depleted blood platelets following renal transplantation. 1990 Thromb. Haemost. pmid:2148845
Hoet B et al. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease. 1990 Thromb. Haemost. pmid:2148849
Cattaneo M et al. Human platelet aggregation and release reaction induced by platelet activating factor (PAF-acether)--effects of acetylsalicylic acid and external ionized calcium. 1985 Thromb. Haemost. pmid:3927505
Wang WJ and Huang TF A novel tetrameric venom protein, agglucetin from Agkistrodon acutus, acts as a glycoprotein Ib agonist. 2001 Thromb. Haemost. pmid:11686327
Jackson C et al. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect. 1989 Thromb. Haemost. pmid:2546286
Davì G et al. Increased thromboxane metabolites excretion in liver cirrhosis. 1998 Thromb. Haemost. pmid:9569186
Sheu JR et al. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets. 2000 Thromb. Haemost. pmid:10823277
Crescente M et al. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings. 2007 Thromb. Haemost. pmid:17549313
Undas A et al. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin. 2007 Thromb. Haemost. pmid:17549314
Homoncik M et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. 2000 Thromb. Haemost. pmid:10739392
Perneby C et al. Dose- and time-dependent antiplatelet effects of aspirin. 2006 Thromb. Haemost. pmid:16601836
Eldor A et al. Effects of dipyrone on prostaglandin production by human platelets and cultured bovine aortic endothelial cells. 1983 Thromb. Haemost. pmid:6346571
Menys VC and Davies JA Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion. 1983 Thromb. Haemost. pmid:6346575
Foo LC et al. Platelets of habitual smokers have reduced susceptibility to aggregating agent. 1991 Thromb. Haemost. pmid:2048056
Gordge MP et al. Platelet function and the bleeding time in progressive renal failure. 1988 Thromb. Haemost. pmid:3187950
Vezza R et al. Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism. 1997 Thromb. Haemost. pmid:9408024
Lessiani G et al. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. 2011 Thromb. Haemost. pmid:21103664
Greer IA et al. Platelet activation in allergic asthma. 1985 Thromb. Haemost. pmid:2931855
Hohlfeld T et al. Antiplatelet effects of ticlopidine are reduced in experimental hypercholesterolemia. 1994 Thromb. Haemost. pmid:7513092
Han P et al. Verapamil and collagen-induced platelet reactions--evidence for a role for intracellular calcium in platelet activation. 1983 Thromb. Haemost. pmid:6415847
Turpeinen AM et al. Replacement of dietary saturated by unsaturated fatty acids: effects of platelet protein kinase C activity, urinary content of 2,3-dinor-TXB2 and in vitro platelet aggregation in healthy man. 1998 Thromb. Haemost. pmid:9798986
Guthikonda S et al. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. 2008 Thromb. Haemost. pmid:18612542
Gresele P et al. Platelet activation markers in patients with peripheral arterial disease--a prospective comparison of different platelet function tests. 1997 Thromb. Haemost. pmid:9423790
Naesh O et al. Platelet function in surgical stress. 1985 Thromb. Haemost. pmid:2935969
Davì G et al. The effect of two low doses of aspirin on whole blood thromboxane and prostacyclin generation in healthy subjects. 1983 Thromb. Haemost. pmid:6417815
Dale J et al. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. 1983 Thromb. Haemost. pmid:6689091
Hornby EJ et al. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion. 1989 Thromb. Haemost. pmid:2529661
Bar J et al. The regulation of platelet aggregation in vitro by interleukin-1beta and tumor necrosis factor-alpha: changes in pregnancy and in pre-eclampsia. 1997 Thromb. Haemost. pmid:9364994
Husted SE et al. Intravenous acetylsalicylic acid--dose-related effects on platelet function and fibrinolysis in healthy males. 1992 Thromb. Haemost. pmid:1412171
Subbiah MT et al. Studies of aggregation and thromboxane B2 synthesis in avian thrombocytes: comparison between atherosclerosis-susceptible and resistant breeds. 1980 Thromb. Haemost. pmid:7455983
Zahavi M et al. Abnormal typical pattern of platelet function and thromboxane generation in unstable angina. 1989 Thromb. Haemost. pmid:2531938
Barrett PA and Butler KD Shortening of platelet survival by induced hypercholesterolaemia in rabbits and its prolongation by anagrelide. 1983 Thromb. Haemost. pmid:6648889
Szczeklik A et al. Prolonged bleeding time, reduced platelet aggregation, altered PAF-acether sensitivity and increased platelet mass are a trait of asthma and hay fever. 1986 Thromb. Haemost. pmid:3563961
Falcon CR et al. The in vitro production of thromboxane B2 by platelets of diabetic patients is normal at physiological concentrations of ionized calcium. 1993 Thromb. Haemost. pmid:8259535
Larsen SB et al. Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. 2012 Thromb. Haemost. pmid:22534977
Cattaneo M et al. Conditions influencing the interaction of asialo von Willebrand factor with human platelets--the effects of external ionized calcium concentration and the role of arachidonate pathway. 1988 Thromb. Haemost. pmid:3146144
Fimognari FL et al. Nocturnal rise of urinary thromboxane B 2 in patients with coronary artery disease. 2005 Thromb. Haemost. pmid:15735822
De Caterina R et al. Organic nitrates: direct antiplatelet effects and synergism with prostacyclin. Antiplatelet effects of organic nitrates. 1988 Thromb. Haemost. pmid:3291182
Teng CM and Ko FN Comparison of the platelet aggregation induced by three thrombin-like enzymes of snake venoms and thrombin. 1988 Thromb. Haemost. pmid:3291184
de Castellarnau C et al. Prostacyclin and thromboxane production by autogenous femoral veins grafted into the arterial circulation of the dog. 1989 Thromb. Haemost. pmid:2665174
Davì G et al. Demonstration of Rickettsia Conorii-induced coagulative and platelet activation in vivo in patients with Mediterranean spotted fever. 1995 Thromb. Haemost. pmid:8584998
Habib A et al. Increased expression of inducible cyclooxygenase-2 in human endothelial cells by antiphospholipid antibodies. 1995 Thromb. Haemost. pmid:8585020
Evangelista V et al. Defibrotide inhibits platelet activation by cathepsin G released from stimulated polymorphonuclear leukocytes. 1992 Thromb. Haemost. pmid:1509406
Rocca B et al. Increased thromboxane biosynthesis in essential thrombocythemia. 1995 Thromb. Haemost. pmid:8607099
Korbut R et al. On the mechanism of thrombolytic action of thromboxane synthetase inhibitors. 1987 Thromb. Haemost. pmid:3324381
Huang TF et al. Mechanism of action of a potent antiplatelet peptide, triflavin from Trimeresurus flavoviridis snake venom. 1991 Thromb. Haemost. pmid:1665595
Totani L et al. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. 2012 Thromb. Haemost. pmid:22436970
Véricel E et al. Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients. 2015 Thromb. Haemost. pmid:25832443
Spowart K et al. Haemostatic effects of ketorolac with and without concomitant heparin in normal volunteers. 1988 Thromb. Haemost. pmid:3266379
Cerletti C et al. Aspirin kinetics and inhibition of platelet thromboxane generation-relevance for a solution of the "aspirin dilemma". 1985 Thromb. Haemost. pmid:4049312
Aoki T et al. Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA2 synthesis. 1998 Thromb. Haemost. pmid:9657446
Larsen SB et al. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. 2013 Thromb. Haemost. pmid:23407706
Dotevall A et al. Cigarette smoking increases thromboxane A2 formation without affecting platelet survival in young healthy females. 1992 Thromb. Haemost. pmid:1455405
De Caterina R et al. Benefit/risk profile of combined antiplatelet therapy with ticlopidine and aspirin. 1991 Thromb. Haemost. pmid:1871711
de Boer A et al. Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers. 1991 Thromb. Haemost. pmid:1722918
De Caterina R et al. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. 1985 Thromb. Haemost. pmid:4082090
Davì G et al. Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus. 1996 Thromb. Haemost. pmid:8819248
Ding YA et al. Potentiation of adrenaline-induced platelet aggregation by angiotensin II. 1985 Thromb. Haemost. pmid:4089801
Blais N et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). 2009 Thromb. Haemost. pmid:19652893
Holme S et al. The effect of albumin bound polyunsaturated fatty acids on human platelets. 1984 Thromb. Haemost. pmid:6719386
Carter AJ and Hanley SP The effect of platelet number and haematocrit on whole blood thromboxane synthesis. 1985 Thromb. Haemost. pmid:4024033
Brox JH et al. The effect of cod liver oil and corn oil on platelets and vessel wall in man. 1981 Thromb. Haemost. pmid:7031981
Strano A et al. Thromboxane formation by platelets and platelet sensitivity to prostacyclin in patients with acute myocardial infarction. 1981 Thromb. Haemost. pmid:7036402
Butler KD et al. The effects of modulation of prostanoid metabolism on the thoracic platelet accumulation induced by intravenous administration of collagen in the guinea-pig. 1986 Thromb. Haemost. pmid:3105104